Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 5/20 | 0.54 |
| ▸ | BCHE | P06276 | 1/20 | 0.51 |
| ▸ | LIPC | P11150 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | LIPE | Q05469 | 1/20 | 0.51 |
| ▸ | ABHD16A | O95870 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 2/20 | 0.44 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11557381 | 0.90 | MGLL (0.44) | MGLLBCHELIPCACHELIPE | |
| SCHEMBL11558642 | 0.89 | ABHD16A (0.51) | MGLLBCHELIPCACHELIPE | |
| SCHEMBL11618056 | 0.87 | MGLL (0.50) | MGLLBCHELIPCACHELIPE | |
| SCHEMBL74675 | 0.87 | ABHD16A (0.57) | MGLLABHD16AFAAH | |
| SCHEMBL30201257 | 0.87 | ABHD16A (0.57) | MGLLABHD16AFAAH | |
| SCHEMBL11556228 | 0.83 | MGLL (0.56) | MGLLBCHELIPCACHELIPE | |
| SCHEMBL11560641 | 0.82 | ABHD16A (0.46) | MGLLABHD16AFAAHADORA3ADORA1 | |
| SCHEMBL11618969 | 0.82 | MGLL (0.55) | MGLLBCHELIPCACHELIPE | |
| SCHEMBL11621692 | 0.82 | MGLL (0.55) | MGLLBCHELIPCACHELIPE | |
| SCHEMBL11619856 | 0.80 | MGLL (0.50) | MGLLBCHELIPCACHELIPE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299264-B2 | Method for producing oxadiazolinone compound and intermediate thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-10-30 | — | — | US | disclosed |
| US-20110207936-A1 | METHOD FOR PRODUCING OXADIAZOLINONE COMPOUND AND INTERMEDIATE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-08-25 | — | — | US | disclosed |
| EP-2357167-A1 | METHOD FOR PRODUCING OXADIAZOLINONE COMPOUND AND INTERMEDIATE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2011-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207936-A1 | METHOD FOR PRODUCING OXADIAZOLINONE COMPOUND AND INTERMEDIATE THEREOF | AHR, CYP1B1, AR | MGLL 4777/4885BCHE 3935/4885LIPC 4408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.